Advertisement


George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

2017 Genitourinary Cancers Symposium

Advertisement

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.



Related Videos

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Kidney Cancer

Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on atezolizumab with or without bevacizumab vs sunitinib in patients with untreated metastatic renal cell carcinoma. (Abstract 431)

Kidney Cancer

Sumanta K. Pal, MD, on Advanced Renal Cancer: Treatment Challenges

Sumanta K. Pal, MD, of the City of Hope, summarizes a session he co-chaired on the opportunities and challenges in systemic therapy for advanced renal cancer, including imaging as a biomarker of response and optimal selection of front-line treatments. (General Session 9)

Kidney Cancer

Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)

Prostate Cancer

L. Michael Glodé, MD, on Prostate Cancer: Results From SWOG S9921

L. Michael Glodé, MD, of the University of Colorado Cancer Center, discusses study findings on adjuvant androgen deprivation vs mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy. (Abstract 2)

Advertisement

Advertisement




Advertisement